May 25, 2017 10:56 AM EDT
News Briefing

New car­dio tar­get ANGPTL3 with promis­ing new stud­ies; Liv­er­pool says Redx is delin­quent; Aslan's $33M Taipei IPO

Emma Yasinski

→ Re­gen­eron and Io­n­is each have pub­li­ca­tions in The New Eng­land Jour­nal of Med­i­cine aimed at a brand new car­dio tar­get ANGPTL3.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times